Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling

Molecular and Cellular Proteomics

Volumn 15, Issue 8, 2016, Pages 2671-2685

  Humphrey, Emily S ^a,b   Su, Shih Ping ^c   Nagrial, Adnan M ^a,b   Hochgrä Fe, Falko ^d   Pajic, Marina ^a,b   Lehrbach, Gillian M ^a   Parton, Robert G ^e   Yap, Alpha S ^e   Horvath, Lisa G ^a,f   Chang, David K ^g   Biankin, Andrew V ^g   Wu, Jianmin ^a,b,h   Daly, Roger J ^b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f The Chris O Brien Lifehouse   (Australia)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTYROSINE;

ANTIBODY AFFINITY; ARTICLE; CANCER CELL; CELL ADHESION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; RANDOM FOREST; CELL SURVIVAL; LIQUID CHROMATOGRAPHY; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PROCEDURES; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; PANCREATIC NEOPLASMS; PHOSPHOTYROSINE; PROTEIN INTERACTION MAPS; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84980480250     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M116.058313     Document Type: Article

References (45)

1. Vogelzang, N. J., Benowitz, S. I., Adams, S., Aghajanian, C., Chang, S. M., Dreyer, Z. E., Janne, P. A., Ko, A. H., Masters, G. A., Odenike, O., Patel, J. D., Roth, B. J., Samlowski, W. E., Seidman, A. D., Tap, W. D., Temel, J. S., Von Roenn, J. H., and Kris, M. G. (2012) Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J. Clin. Oncol. 30, 88-109
2. Paulson, A. S., Tran Cao, H. S., Tempero, M. A., and Lowy, A. M. (2013) Therapeutic advances in pancreatic cancer. Gastroenterology 144, 1316-1326
3. Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M. C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A. M., Wu, J., Chang, D. K., Cowley, M. J., Gardiner, B. B., Song, S., Harliwong, I., Idrisoglu, S., Nourse, C., Nourbakhsh, E., Manning, S., Wani, S., Gongora, M., Pajic, M., Scarlett, C. J., Gill, A. J., Pinho, A. V., Rooman, I., Anderson, M., Holmes, O., Leonard, C., Taylor, D., Wood, S., Xu, Q., Nones, K., Fink, J. L., Christ, A., Bruxner, T., Cloonan, N., Kolle, G., Newell, F., Pinese, M., Mead, R. S., Humphris, J. L., Kaplan, W., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chou, A., Chin, V. T., Chantrill, L. A., Mawson, A., Samra, J. S., Kench, J. G., Lovell, J. A., Daly, R. J., Merrett, N. D., Toon, C., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Kakkar, N., Zhao, F., Wu, Y. Q., Wang, M., Muzny, D. M., Fisher, W. E., Brunicardi, F. C., Hodges, S. E., Reid, J. G., Drummond, J., Chang, K., Han, Y., Lewis, L. R., Dinh, H., Buhay, C. J., Beck, T., Timms, L., Sam, M., Begley, K., Brown, A., Pai, D., Panchal, A., Buchner, N., De Borja, R., Denroche, R. E., Yung, C. K., Serra, S., Onetto, N., Mukhopadhyay, D., Tsao, M. S., Shaw, P. A., Petersen, G. M., Gallinger, S., Hruban, R. H., Maitra, A., Iacobuzio-Donahue, C. A., Schulick, R. D., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Capelli, P., Corbo, V., Scardoni, M., Tortora, G., Tempero, M. A., Mann, K. M., Jenkins, N. A., Perez-Mancera, P. A., Adams, D. J., Largaespada, D. A., Wessels, L. F., Rust, A. G., Stein, L. D., Tuveson, D. A., Copeland, N. G., Musgrove, E. A., Scarpa, A., Eshleman, J. R., Hudson, T. J., Sutherland, R. L., Wheeler, D. A., Pearson, J. V., McPherson, J. D., Gibbs, R. A., and Grimmond, S. M. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405
4. Waddell, N., Pajic, M., Patch, A. M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., Quek, K., Quinn, M. C., Robertson, A. J., Fadlullah, M. Z., Bruxner, T. J., Christ, A. N., Harliwong, I., Idrisoglu, S., Manning, S., Nourse, C., Nourbakhsh, E., Wani, S., Wilson, P. J., Markham, E., Cloonan, N., Anderson, M. J., Fink, J. L., Holmes, O., Kazakoff, S. H., Leonard, C., Newell, F., Poudel, B., Song, S., Taylor, D., Waddell, N., Wood, S., Xu, Q., Wu, J., Pinese, M., Cowley, M. J., Lee, H. C., Jones, M. D., Nagrial, A. M., Humphris, J., Chantrill, L. A., Chin, V., Steinmann, A. M., Mawson, A., Humphrey, E. S., Colvin, E. K., Chou, A., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Pettitt, J. A., Merrett, N. D., Toon, C., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Jamieson, N. B., Graham, J. S., Niclou, S. P., Bjerkvig, R., Grutzmann, R., Aust, D., Hruban, R. H., Maitra, A., Iacobuzio-Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Falconi, M., Zamboni, G., Tortora, G., Tempero, M. A., Gill, A. J., Eshleman, J. R., Pilarsky, C., Scarpa, A., Musgrove, E. A., Pearson, J. V., Biankin, A. V., and Grimmond, S. M. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501
5. Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A. M., Gingras, M. C., Miller, D. K., Christ, A. N., Bruxner, T. J., Quinn, M. C., Nourse, C., Murtaugh, L. C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M. J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P. J., Cloonan, N., Kassahn, K. S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L. N., Evers, L., Wu, J., Pinese, M., Cowley, M. J., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chantrill, L. A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Lovell, J. A., Merrett, N. D., Toon, C. W., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N. B., Graham, J. S., Duthie, F., Oien, K., Hair, J., Grutzmann, R., Maitra, A., Iacobuzio- Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G. M., Australian Pancreatic Cancer Genome, I., Munzy, D. M., Fisher, W. E., Karim, S. A., Eshleman, J. R., Hruban, R. H., Pilarsky, C., Morton, J. P., Sansom, O. J., Scarpa, A., Musgrove, E. A., Bailey, U. M., Hofmann, O., Sutherland, R. L., Wheeler, D. A., Gill, A. J., Gibbs, R. A., Pearson, J. V., Waddell, N., Biankin, A. V., and Grimmond, S. M. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47-52
6. Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., Feiler, H. S., Ko, A. H., Olshen, A. B., Danenberg, K. L., Tempero, M. A., Spellman, P. T., Hanahan, D., and Gray, J. W. (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500-503
7. Jimeno, A., Tan, A. C., Coffa, J., Rajeshkumar, N. V., Kulesza, P., Rubio- Viqueira, B., Wheelhouse, J., Diosdado, B., Messersmith, W. A., Iacobuzio- Donahue, C., Maitra, A., Varella-Garcia, M., Hirsch, F. R., Meijer, G. A., and Hidalgo, M. (2008) Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res. 68, 2841-2849
8. Roesli, C. (2015) Recent advances in proteomically subtyping pancreatic ductal adenocarcinomas and their potential clinical impact. Expert Rev. Proteomics 12, 5-8
9. Britton, D., Zen, Y., Quaglia, A., Selzer, S., Mitra, V., Lobetaner, C., Jung, S., Bohm, G., Schmid, P., Prefot, P., Hoehle, C., Koncarevic, S., Gee, J., Nicholson, R., Ward, M., Castellano, L., Stebbing, J., Zucht, H. D., Sarker, D., Heaton, N., and Pike, I. (2014) Quantification of pancreatic cancer proteome and phosphorylome: Indicates molecular events likely contributing to cancer and activity of drug targets. PloS One 9, e90948
10. Friess, H., Yamanaka, Y., Kobrin, M. S., Do, D. A., Buchler, M. W., and Korc, M. (1995) Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin. Cancer Res. 1, 1413-1420
11. Koorstra, J. B., Karikari, C. A., Feldmann, G., Bisht, S., Rojas, P. L., Offerhaus, G. J., Alvarez, H., and Maitra, A. (2009) The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol. Therapy 8, 618-626
12. Pettazzoni, P., Viale, A., Shah, P., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., Huang-Hobbs, E., Corti, D., Sanchez, N., Nezi, L., Marchesini, M., Kapoor, A., Yao, W., Francesco, M. E., Petrocchi, A., Deem, A. K., Scott, K., Colla, S., Mills, G. B., Fleming, J. B., Heffernan, T. P., Jones, P., Toniatti, C., DePinho, R. A., and Draetta, G. F. (2015) Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res. 75, 1091-1101
13. Ueda, S., Ogata, S., Tsuda, H., Kawarabayashi, N., Kimura, M., Sugiura, Y., Tamai, S., Matsubara, O., Hatsuse, K., and Mochizuki, H. (2004) The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: Poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29, e1-8
14. Nagaraj, N. S., Smith, J. J., Revetta, F., Washington, M. K., and Merchant, N. B. (2010) Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol. Cancer Therapeutics 9, 2322-2332
15. Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., and Testa, J. R. (1998) Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinogenesis 21, 81-86
16. Foo, W. C., Rashid, A., Wang, H., Katz, M. H., Lee, J. E., Pisters, P. W., Wolff, R. A., Abbruzzese, J. L., Fleming, J. B., and Wang, H. (2013) Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Human Pathol. 44, 1024-1030
17. Hochgrafe, F., Zhang, L., O'Toole, S. A., Browne, B. C., Pinese, M., Porta Cubas, A., Lehrbach, G. M., Croucher, D. R., Rickwood, D., Boulghourjian, A., Shearer, R., Nair, R., Swarbrick, A., Faratian, D., Mullen, P., Harrison, D. J., Biankin, A. V., Sutherland, R. L., Raftery, M. J., and Daly, R. J. (2010) Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res. 70, 9391-9401
18. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., Hu, Y., Tan, Z., Stokes, M., Sullivan, L., Mitchell, J., Wetzel, R., Macneill, J., Ren, J. M., Yuan, J., Bakalarski, C. E., Villen, J., Kornhauser, J. M., Smith, B., Li, D., Zhou, X., Gygi, S. P., Gu, T. L., Polakiewicz, R. D., Rush, J., and Comb, M. J. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203
19. Vizcaino, J. A., Deutsch, E. W., Wang, R., Csordas, A., Reisinger, F., Rios, D., Dianes, J. A., Sun, Z., Farrah, T., Bandeira, N., Binz, P. A., Xenarios, I., Eisenacher, M., Mayer, G., Gatto, L., Campos, A., Chalkley, R. J., Kraus, H. J., Albar, J. P., Martinez-Bartolome, S., Apweiler, R., Omenn, G. S., Martens, L., Jones, A. R., and Hermjakob, H. (2014) Proteome- Xchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223-226
20. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnol. 26, 1367-1372
21. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., and Mann, M. (2011) Andromeda: A peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794-1805
22. Hrydziuszko, O., and Viant, M. R. (2012) Missing values in mass spectrometry based metabolomics: An undervalued step in the data processing pipeline. Metabolomics 8, 161-174
23. Xie, C., Mao, X., Huang, J., Ding, Y., Wu, J., Dong, S., Kong, L., Gao, G., Li, C. Y., and Wei, L. (2011) KOBAS 2.0: A web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 39, W316-322
24. Cowley, M. J., Pinese, M., Kassahn, K. S., Waddell, N., Pearson, J. V., Grimmond, S. M., Biankin, A. V., Hautaniemi, S., and Wu, J. (2012) PINA v2.0: Mining interactome modules. Nucleic Acids Res. 40, D862-865
25. Qian, J., Niu, J., Li, M., Chiao, P. J., and Tsao, M. S. (2005) In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res. 65, 5045-5053
26. Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., and Settleman, J. (2009) A gene expression signature associated with 'K-Ras addiction' reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489-500
27. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., Parulekar, W., and National Cancer Institute of Canada Clinical Trials, G. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966
28. Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., Smyla, J. K., Anderson, J. M., Kim, H. J., Bentrem, D. J., Talamonti, M. S., Iacobuzio-Donahue, C. A., Hollingsworth, M. A., and Yeh, J. J. (2015) Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genetics 47, 1168-1178
29. Mann, K. M., Ward, J. M., Yew, C. C., Kovochich, A., Dawson, D. W., Black, M. A., Brett, B. T., Sheetz, T. E., Dupuy, A. J., Australian Pancreatic Cancer Genome, I., Chang, D. K., Biankin, A. V., Waddell, N., Kassahn, K. S., Grimmond, S. M., Rust, A. G., Adams, D. J., Jenkins, N. A., and Copeland, N. G. (2012) Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 109, 5934-5941
30. Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W. C., Mansour, J., Mollaee, M., Wagner, K. U., Koduru, P., Yopp, A., Choti, M. A., Yeo, C. J., McCue, P., White, M. A., and Knudsen, E. S. (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744
31. Golan-Gerstl, R., Cohen, M., Shilo, A., Suh, S. S., Bakacs, A., Coppola, L., and Karni, R. (2011) Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res. 71, 4464-4472
32. Lefave, C. V., Squatrito, M., Vorlova, S., Rocco, G. L., Brennan, C. W., Holland, E. C., Pan, Y. X., and Cartegni, L. (2011) Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J. 30, 4084-4097
33. Ostareck-Lederer, A., Ostareck, D. H., Cans, C., Neubauer, G., Bomsztyk, K., Superti-Furga, G., and Hentze, M. W. (2002) c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs. Mol. Cell. Biol. 22, 4535-4543
34. Ostrowski, J., Schullery, D. S., Denisenko, O. N., Higaki, Y., Watts, J., Aebersold, R., Stempka, L., Gschwendt, M., and Bomsztyk, K. (2000) Role of tyrosine phosphorylation in the regulation of the interaction of heterogenous nuclear ribonucleoprotein K protein with its protein and RNA partners. J. Biol. Chem. 275, 3619-3628
35. White, R., Gonsior, C., Kramer-Albers, E. M., Stohr, N., Huttelmaier, S., and Trotter, J. (2008) Activation of oligodendroglial Fyn kinase enhances translation of mRNAs transported in hnRNP A2-dependent RNA granules. J. Cell Biol. 181, 579-586
36. Maguire, S. L., Leonidou, A., Wai, P., Marchio, C., Ng, C. K., Sapino, A., Salomon, A. V., Reis-Filho, J. S., Weigelt, B., and Natrajan, R. C. (2015) SF3B1 mutations constitute a novel therapeutic target in breast cancer. J. Pathol. 235, 571-580
37. Perera, R. M., and Bardeesy, N. (2012) Ready, set, go: The EGF receptor at the pancreatic cancer starting line. Cancer cell 22, 281-282
38. Kim, M. S., Zhong, Y., Yachida, S., Rajeshkumar, N. V., Abel, M. L., Marimuthu, A., Mudgal, K., Hruban, R. H., Poling, J. S., Tyner, J. W., Maitra, A., Iacobuzio-Donahue, C. A., and Pandey, A. (2014) Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Mol. Cell. Proteomics 13, 2803-2811
39. Giaginis, C., Tsourouflis, G., Zizi-Serbetzoglou, A., Kouraklis, G., Chatzopoulou, E., Dimakopoulou, K., and Theocharis, S. E. (2010) Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. Pathol. Oncol. Res. 16, 267-276
40. Lu, Z., Zhang, Y., Li, Z., Yu, S., Zhao, G., Li, M., Wang, Z., Wang, Q., and Yang, Y. (2012) Overexpression of the B-type Eph and ephrin genes correlates with progression and pain in human pancreatic cancer. Oncol. Lett. 3, 1207-1212
41. Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., Chin, L., and DePinho, R. A. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290
42. Kothari, V., Wei, I., Shankar, S., Kalyana-Sundaram, S., Wang, L., Ma, L. W., Vats, P., Grasso, C. S., Robinson, D. R., Wu, Y. M., Cao, X., Simeone, D. M., Chinnaiyan, A. M., and Kumar-Sinha, C. (2013) Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discovery 3, 280-293
43. Navas, C., Hernandez-Porras, I., Schuhmacher, A. J., Sibilia, M., Guerra, C., and Barbacid, M. (2012) EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22, 318-330
44. Frolov, A., Schuller, K., Tzeng, C. W., Cannon, E. E., Ku, B. C., Howard, J. H., Vickers, S. M., Heslin, M. J., Buchsbaum, D. J., and Arnoletti, J. P. (2007) ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol. Therapy 6, 548-554
45. Liles, J. S., Arnoletti, J. P., Tzeng, C. W., Howard, J. H., Kossenkov, A. V., Kulesza, P., Heslin, M. J., and Frolov, A. (2010) ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biol. Therapy 10, 555-563